Suzanne R. Fanning
Expertise in
40
conditions

Dr. Suzanne R. Fanning

Oncology | Hematology Oncology
65 International Drive, 
Greenville, SC 
Accepting New Patients
Referral required
Before you request
Expertise in
40
conditions
65 International Drive, 
Greenville, SC 

Overview

Suzanne Fanning is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina.

Dr. Fanning is highly rated in 40 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Fanning is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 7 clinical trials. Dr. Fanning is currently accepting new patients.

Specialties

Oncology
Hematology Oncology

Licenses

Internal Medicine in SC

Board Certifications

American Board Of Internal Medicine

Fellowships

Cleveland Clinic Foundation

Hospital Affiliations

Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Hillcrest Hospital
Prisma Health Oconee Memorial Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Prisma Health Cancer Institute – Eastside
65 International Drive, Greenville, SC 29615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Biological
Study Drug: lisocabtagene maraleucel
Study Phase: Phase 2
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)
Enrollment Status: Completed
Publish Date: December 20, 2023
Intervention Type: Biological
Study Drug: Lisocabtagene maraleucel
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

14 Total Publications

Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
Journal: Current medical research and opinion
Published: August 26, 2026
Similar Doctors
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Expertise in
76
conditions
Dr. Britt H. Bolemon
Oncology | Hematology Oncology
Referral required
Before you request

Prisma Health Cancer Institute – Eastside

65 International Drive, 
Greenville, SC 
 (0.1 miles away)
864-987-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Britt Bolemon is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina. Dr. Bolemon is highly rated in 76 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Lung Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Bolemon is board certified in American Board Of Internal Medicine. Dr. Bolemon is currently accepting new patients.

Expertise in
93
conditions
Dr. Steven A. Madden
Hematology Oncology | Hematology | Oncology
Expertise in
93
conditions
Dr. Steven A. Madden
Hematology Oncology | Hematology | Oncology
Referral may be required

Advanced Oncology Newberry

298 Commerce Dr, 
Newberry, SC 
 (56.1 miles away)
803-321-3232
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Madden is a Hematologist Oncology specialist and a Hematologist practicing medicine in Newberry, South Carolina. Dr. Madden is highly rated in 93 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Madden is currently accepting new patients.

Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Expertise in
23
conditions
Dr. Carla W. Jorgensen
Oncology | Hematology Oncology
Referral may be required
Before you request

Prisma Health Cancer Institute Multidisciplinary Center – Faris Rd.

890 West Faris Road, Suite 320, 
Greenville, SC 
 (5.5 miles away)
864-455-1200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carla Jorgensen is an Oncologist and a Hematologist Oncology provider practicing medicine in Greenville, South Carolina. Dr. Jorgensen is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Jorgensen is board certified in American Board Of Internal Medicine. Dr. Jorgensen is currently accepting new patients.

Frequently Asked Questions about Dr. Suzanne R. Fanning

How do I make an appointment with Dr. Suzanne R. Fanning?

You can book an appointment with Dr. Suzanne R. Fanning by calling their office at 864-987-7000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Suzanne R. Fanning a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Suzanne R. Fanning is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Suzanne R. Fanning specialize in?

While Dr. Suzanne R. Fanning is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, and Mantle Cell Lymphoma (MCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Suzanne R. Fanning participate in research or clinical trials?

Yes. Dr. Suzanne R. Fanning has published 14 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. Suzanne R. Fanning's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Suzanne R. Fanning accept my insurance?

Dr. Suzanne R. Fanning accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-987-7000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fanning's expertise for a condition
ConditionClose
    View All 19 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 99 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile